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Abstract
The objective of the study was to investigate the anti-tumour effect of ethanol extract of Solanum lyratum Thunb.
in S180 tumour-bearing mice, and to preliminarily explore its mechanism of action. Methods: Mice were made
into S180 solid tumour model, grouped and administered. Tumour inhibition rate was measured by harvesting the
tumours. Serum IL-2, TNF-a contents were measured by taking blood samples, and thymus index and spleen index
were measured by harvesting the thymus and spleen. The results showed that the Solanum lyratum Thunb. extract had
certain tumour inhibitory effect, which can elevate the serum IL-2, TNF-a contents, and increase the thymus and
spleen indices to a certain extent. The study concluded that Solanum lyratum Thunb. extract has certain in vivo
anti-tumour effect which may be exerted through enhancing the body immunity.
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Introduction
Solanum lyratum Thunb. is the dried whole plant of Solanum lyratum Thunb., which belongs to the family Solanaceae.
It was originally recorded in the "Shen Nong's Herbal Classic" (Xu, 1994) as top grade, bitter and pungent in taste, slightly
cold in nature, and entering the liver and gall bladder meridians. Currently, it is mainly used in the clinical treatment of colds,
fever, hot and humid jaundice, dysentery, nephritis, oedema, cholecystitis, cholelithiasis, cervical erosion, leucorrhoea,
etc. Recently, the compounds that have been isolated from Solanum lyratum Thunb. by researchers at home and abroad
mainly include the following categories: saponin compounds (Kotaro et al, 1985; Kotaro et al, 1981; Shoji et al, 1985; Stero
et al, 1986), organic acids (Yang et al, 2002; Yin et al, 2010), flavonoids compounds (Li, 2006; Wang, 2004; Yin et al,
2010), terpenoids, etc. And the studies on its pharmacological activities are mainly focused on aspects such as
anti-cancer (Dan et al, 2001; Ren et al, 2006; Yu et al, 2008), anti-oxidation (Wei et al, 2009), and anti-bacteria (Cui et al,
2004). In this paper, animal model of S180 solid tumour was used to study the tumour inhibitory mechanism of extract of
Solanum lyratum Thunb.
Materials and Methods
Drugs and Reagents
Solanum lyratum Thunb. decoction pieces were identified by Professor Wang Ping, and was deposited to the Pharmacy
Centre of PLA General Hospital. (They were purchased from Jiangxi Nanhua Medicine Co., Ltd.). CTX was purchased from
Jiangsu Hengrui Medicine Co., Ltd.). Trypan blue staining solution was also used.
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Main Instruments
The main instruments used in the study included the following: FM-2000A dual probe γ immune counter (Xi'an Kaipu 
Electromechanical Co., Ltd.); AE31 inverted phase contrast microscope (Motic); SW-CJ-IF clean bench (Suzhou Purification
Equipment Factory); low-temperature refrigerated centrifuge (Eppendorf, Germany); electronic balance (Beijing Sartorius
Instrument System Co., Ltd.); cell counting chamber (Shanghai Qiujing Biochemical Instrument Factory).
Experimental Animals
Kunming mice, half male and half female, weighing 18~22 g, were purchased from the Laboratory Animal Center of PLA
General Hospital. All experimental procedures were approved by the Animal Research Ethics Committee of Yunnan Medical
College University
S180 Tumour Lines
S180 tumour lines were purchased from the KeyGEN Biotech Co., Ltd.
Preparation of extract of Solanum lyratum Thunb.
Dried crude Solanum lyratum Thunb. was crushed and 50 g was weighed. It was then added with a 20-fold
volume of 70% ethanol, and ultrasonically extracted three times with 30 min each time. After the extracts were
combined and cryogenically concentrated, NKA-9 resin was applied, and column was washed with 50% ethanol.
After the column effluent was cryo-concentrated and freeze-dried, Solanum lyratum Thunb. extract powder was
obtained and was diluted to a certain concentration when using.
Determination of tumour cell concentration
According to the Response Evaluation Criteria in Solid Tumours, if the average weight of tumours in mice of negative
control group is less than 1 g or tumour weights of 20% of the mice are less than 400 mg, it indicates the tumour growth is
poor. During the therapy, if mortality of mice in administration group exceeds 20%, or more than 15% of the mice has a
decrease (self control) of average weight (after tumour removal), then it indicates the drug is toxic and the dose should be
reduced. The inoculum concentration of tumour cells is the key to this experiment. When the amount of inoculated tumour
cells is too small, there will be no sarcoma growth or tumour weight will be too light, thus drug efficacy could not be
evaluated. When the amount of inoculated tumour cells is too high, the drug in the experimental group could not inhibit the
growth of tumour, and pharmacodynamic effect could not be manifested. Therefore, the concentration of inoculated tumour
cells must be carefully selected. Tumour cells with tumour mass weight of about 2 g 10 days after inoculation were selected
as the final inoculum concentration.
Under sterile conditions, a certain amount was inoculated into healthy Kunming mice. After about 7 days, 0.1 mL of
S180 ascites were diluted to 100-fold with normal saline. 0.5 mL of the tumour cell dilution was taken and added with 0.5 mL
of 0.2% trypan blue dye, mixed well, and then counted under a microscope using cell counting chamber (leukocytes counting
method), and the number of leukocytes in original ascites were obtained.
The original ascites was prepared into tumour cell suspension with number of tumour cells of 105, 106,
107, 108 cells/mL-1 with normal saline, and inoculated into the forelimb armpit of three groups of Kunming mice respectively.
Each mouse was inoculated with 0.2 mL, and each group contained eight mice. 10 days later, the mice were sacrificed, and
tumours were harvested and weighed from each group of animals.
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Cell Culturing
The cells were made into single cell suspension, and the number of cells was adjusted according to the data obtained
from the above experiment. The cell suspension was implanted into the abdominal cavity of mice with 0.2 mL per mouse
under sterile conditions, and abdominal distension status of mice was observed daily. 7 days later, peritoneal effusion was
extracted from mice.
Animal Model Building (Li et al, 2006)
7 days after the inoculation, the mice whose abdominal circumference was increased to the maximum were sacrificed by
cervical dislocation. After abdomen disinfection, abdominal cavity was cut open, and ascites were extracted with 1 mL sterile
syringe. The ascites were diluted with PBS, centrifuged at 1000 rpm/min for 10 min, and then the supernatant was discarded.
Living cells were counted by trypan blue staining, and the number of tumour cells was adjusted to 1×107 cells/mL. 50 mice
were picked and their right armpit skin was disinfected. Tumour cell suspension was subcutaneously injected to the right
forelimb armpit of mice using 1 mL sterile syringe with 0.2 mL per mouse to induce the solid tumour model.
Grouping and Treatment
24 hours after inoculation, the 50 mice were randomly divided into 5 groups, namely the model group, CTX group, and
Solanum lyratum Thunb. extract high-, medium-, and low-dose groups. Each group contained 10 mice. All mice were given
enough food and water, and each group of mice was weighed and the weights were recorded. Administration method and
dose were determined by referencing the “Experimental Methodology of TCM Pharmacology” (Li et al, 2006). Solanum
lyratum Thunb. high-, medium-, and low-doses were introduced. Mental state, activity and feeding status of the mice were
observed daily. On the 11th day after administration and weighing, blood was sampled from the eyeballs, and centrifuged to
obtain serum, followed by measurement of serum IL-2, TNF-a contents by radioimmunoassay. After blood collection, the
mice were sacrificed. Tumours were harvested and weighed. Tumour inhibition rate was calculated according to the
following formula:
Tumour inhibition rate = (average tumour weight of control group - average tumour weight of experimental group)
/ average tumour weight of control group × 100%
Mouse thymus and spleen were harvested and weighed. The ratio of thymus or spleen weight (mg) to body
weight (10g) was taken as the thymus or spleen index.
Statistical Methods
Experimental data were analysed using the SPSS 13.0 software, and pairwise comparisons among groups
were performed using one-way ANOVA.
Results
Selection of concentration of S180 sarcoma cells
The results for selection of S180 sarcoma cell concentration are shown in Table 1. The results show that when
the tumour cell concentration is 105 cells/mL, tumour weight is very light, which only has a few tiny granules. It
is more appropriate to select tumour cell concentration with tumour mass weight of about 2 g according to the
requirements of the animal experimental methodology. Therefore, 107 cells/mL were selected as the final
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inoculum concentration.
Table 1: Investigation of inoculum concentration of S180 sarcoma cells
Cell
concentrat
ion
(cells/mL)
Tumour weight (g) Mean (g)
105 0.05 0.08 0.13 0.04 0.02 0.14 0.08
106 0.87 0.96 1.22 1.08 0.68 1.05 0.98
107 1.95 1.35 1.44 2.39 2.01 1.78 1.82
108 3.78 2.67 3.54 2.31 3.14 3.63 3.18
Effect of Solanum lyratum Thunb. extract on body weight of mice
The changes in body weight of mice before and after the experiment are shown in Table 2. Except for the CTX group
where weight gain is not obvious, body weights were significantly increased in all of the experimental groups. But the
amount of increase is less when compared with the model group, and the amount of increase is basically negatively correlated
with the dose.
Table 2: Effect of Solanum lyratum Thunb. extract on change in body weight of S180 tumour-bearing mice before and
after experiment (
—
X ±S，n=10)
Group Dose (g crude
drug/Kg)
Number of
animals
Average body weight (g) of
mice before experiment
Average body weight (g) of
mice after experiment
Model group - 10 22.87±2.53 30.34±4.15
CTX group 0.02g 10 22.37±2.64 25.18±3.66
Solanum lyratum Thunb.
high-dose group
28 10 22.65±2.28 28.71±4.37
Solanum lyratum Thunb.
medium-dose group
14 10 22.29±2.75 29.73±4.54
Solanum lyratum Thunb.
low-dose group
7 10 22.51±2.21 30.31±5.11
Effect of Solanum lyratum Thunb. extract on tumour weight and tumour inhibition rate
The results for the effect of Solanum lyratum Thunb. extract on tumour weight and tumour inhibition rate are as
shown in Table 3. There is a highly significant difference (P<0.01) in tumour weight of the Solanum lyratum Thunb.
high-dose group compared with the model group. Tumour weight of Solanum lyratum Thunb. medium-dose group also
showed a significant difference (P<0.05) compared with the model group, and the tumour inhibition rates of the
two groups were both greater than 30%, suggesting that the Solanum lyratum Thunb. extract has a significant
inhibitory effect on solid tumour in S180 tumour-bearing mice. In the Solanum lyratum Thunb. low-dose group,
tumour weight was also reduced compared with the model group, but there was no significant difference.
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Effect of Solanum lyratum Thunb. extract on serum IL-2 and TNF-a contents in mice
The effect of Solanum lyratum Thunb. extract on serum IL-2 and TNF-a contents in mice is as shown in Table 4.
Compared with the model group, IL-2 level was decreased (P<0.01) and TNF-a was slightly increased but not significant in
CTX group. IL-2, TNF-a contents were increased greatly (P<0.01) in Solanum lyratum Thunb. high-dose group. IL-2, TNF-a
contents were also increased significantly (P<0.05 and P<0.01) in Solanum lyratum Thunb. medium-dose group. IL-2 was not
changed obviously in Solanum lyratum Thunb. low-dose group. From this result, we can see that the Solanum lyratum Thunb.
extract can increase IL-2, TNF-a contents, thereby enhancing the body's ability to kill tumour cells, and exerting the
inhibitory effect.
Table 3: Effect of Solanum lyratum Thunb. extract on tumour weight and tumour inhibition rate
Group Dose (g crude
drug/Kg)
Number of
animals
Tumour
weight (g)
Tumour inhibition
rate (%)
Model group - 10 2.15±0.44 -
CTX group 0.02g 10 0.76±0.31** 64.65
Solanum lyratum Thunb. high-dose
group
28 10 1.21±0.34** 43.72
Solanum lyratum Thunb.
medium-dose group
14 10 1.41±0.38* 34.42
Solanum lyratum Thunb. low-dose
group
7 10 1.91±0.52 11.16
Comparison with the model group, *P<0.05; **P<0.01
Table 4: Effect of Solanum lyratum Thunb. extract on serum IL-2 and TNF-a contents in S180 tumour-bearing mice (
—
X ±S)
Group Dose (g crude
drug/Kg)
Number of
animals
IL-2 (ng/mL) TNF-a
(ng/mL)
Model group - 10 12.418±4.531 0.521±0.072
CTX group 0.02g 10 9.557±1.548** 0.579±0.063
Solanum lyratum Thunb. high-dose
group
28 10 16.198±3.144** 0.754±0.087**
Solanum lyratum Thunb. medium-dose
group
14 10 15.475±2.9794* 0.711±0.108**
Solanum lyratum Thunb. low-dose
group
7 10 14.495±2.129 0.657±0.078*
Comparison with the model group, *P<0.05; **P<0.01
Effect of Solanum lyratum Thunb. extract on immune organ thymus index and spleen index in S180
tumour-bearing mice
The effect of Solanum lyratum Thunb. extract on immune organ thymus index and spleen index in S180
tumour-bearing mice is shown in Table 5. Compared with the model group, thymus and spleen weights were
reduced. And thymus index and spleen index were both decreased in CTX group, while thymus index and spleen
index were all increased in each of the Solanum lyratum Thunb. extract does groups, suggesting that the extract can
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enhance the body’s immune function, improving the tumour cell inhibitory effect to some extent.
Table 5: Effect of Solanum lyratum Thunb. extract on immune organ thymus index and spleen index in S180
tumour-bearing mice
Group Thymus index (mg/10 g weight) Spleen index (mg/10 g weight)
Model group 19.3±3.4 54.7±4.6
CTX group 16.9±4.3 52.5±5.8
Solanum lyratum Thunb. high-dose
group
24.4±5.1 62.7±4.9
Solanum lyratum Thunb.
medium-dose group
21.4±3.6 61.2±6.8
Solanum lyratum Thunb. low-dose
group
20.5±3.3 57.5±5.2
Discussion
As an anticancer drug, CTX has side effects such as leucopoenia, and decreased immune function (Jia and Lu, 1996).
Body weight is the most direct reflection of drug toxicity in the S180 sarcoma experiment. After tumour weight of mice in
CTX group and negative group was removed respectively, the body weight of mice in CTX group was 3-5 g lighter than that
of the negative group, while the body weight of mice in experimental group was 3-5 g heavier than negative group after
removal of tumour weight of mice in experimental group and negative group. Therefore, although Solanum lyratum Thunb. is
toxic, its toxicity is far less than CTX. Inhibition of tumour growth and shrinkage of tumour size is an important indicator in
evaluating the efficacy of anticancer therapy of antineoplastic drugs. This experiment demonstrated that the Solanum lyratum
Thunb. extract can exert inhibitory effect on growth of tumours in S180 tumour-bearing mice. And based on its in vivo
antitumour effect, its effect on immune function was further explored, and it was initially confirmed that the extract has the
effect of enhancing immune function. Its exact mechanism of action still needs more in-depth studies.
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